Clinical Trial Detail

NCT ID NCT02498613
Title A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Recruitment Recruiting
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

lung small cell carcinoma

triple-receptor negative breast cancer

lung non-small cell carcinoma

pancreatic adenocarcinoma


Cediranib + Olaparib

Age Groups: senior adult

No variant requirements are available.